Jazz Pharmaceuticals PLC $JAZZ Position Increased by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 42.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,797 shares of the specialty pharmaceutical company’s stock after buying an additional 4,675 shares during the period. Philip James Wealth Mangement LLC’s holdings in Jazz Pharmaceuticals were worth $1,676,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after buying an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. grew its position in Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after purchasing an additional 74,501 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its position in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares in the last quarter. Swedbank AB grew its position in Jazz Pharmaceuticals by 10.0% during the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company’s stock worth $136,831,000 after purchasing an additional 100,211 shares in the last quarter. Finally, Perpetual Ltd grew its position in Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock worth $118,212,000 after purchasing an additional 357,784 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective on the stock. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Royal Bank Of Canada lifted their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $178.93.

Jazz Pharmaceuticals Stock Up 3.9%

Jazz Pharmaceuticals stock opened at $136.90 on Thursday. The company has a market capitalization of $8.30 billion, a P/E ratio of -20.34, a P/E/G ratio of 8.17 and a beta of 0.28. The firm’s fifty day simple moving average is $122.95 and its 200-day simple moving average is $115.86. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.